31 May 2023

Physiomics plc

("Physiomics" or the "Company")

Collaboration with The University of Sheffield

Physiomics plc (AIM: PYC), a leading mathematical modelling company supporting oncology drug development and personalised medicine solutions, is pleased to announce that it is supporting The University of Sheffield (the "University") with research into an insect (Drosophila melanogaster) model of cancer treatment that could be used to screen potential new drugs prior to pre-clinical testing in more traditional mouse models of cancer.  This new approach could provide important insights into the development of new cancer therapies as well as potentially reduce the number of pre-clinical animals involved in the drug development process.

Principal investigator Dr Kyra Campbell of the University is the beneficiary of a three-year grant from the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), awarded in December 2021, which has funded a significant programme of research at the University and other institutions where her co-investigators are based.

The University successfully applied for funding under the UK Research and Innovation (UKRI) Higher Education Innovation Funding (HEIF) scheme, part of which will be used to retain Physiomics for a pilot project to analyse data generated by its innovative new testing platform in order to better understand how the platform might guide later stages of pharmaceutical research into cancer therapies, including pre-clinical and human studies.

The project is expected to be concluded over the next two months, and a longer-term collaboration is currently under discussion.

Physiomics CEO, Dr Jim Millen commented:

"We are delighted to have been selected by The University of Sheffield to support this highly innovative research program with our analytical and modelling capabilities.  We look forward to working with Dr Campbell and her colleagues and believe that both our analytical capabilities, as well as our contacts and experience within the pharmaceutical industry, could add real value to the initiative."

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc combines cutting edge PKPD and QSP modelling techniques with cancer biology expertise, to help biotech and pharma companies streamline their drug development journeys.

Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design of pre-clinical and clinical studies.

Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.